Logo ResMed

ResMed (RMD) stock: analyst price target and their real reliability

Live quote · data updated Aug 28, 2026
ResMed · Health Care · ref. ETF XLV · 50 calls · price $235.76
🏆JPI 2026 portfoliosSee tracking →
What the company does: ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally.

📈 ResMed (RMD) stock price

$235.76-14.4% over range
Aug 28, 25low $182.82 · high $283.28Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
22% recommend buying · 9 analysts
📊 JPI status : ResMed has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
⚠️ The stock trades above the median target: it has beaten expectations. The “Hold” reflects conviction on the company, but the remaining quantified upside is low/negative.

🎯 RMD price target & analyst consensusprice $236

The price target · all analysts combined (9 targets)
Highest target · 1 firm of 9$255+8.2%
Median target · of 9 targets$230-2.4%
Lowest target · 1 firm of 9$215-8.8%
Current price$235.76
Where these 9 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price 222% $244 ↔ $255
Below 778% $215 ↔ $235
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Jefferies72% of its targets hit on this sector (380 calls tested). It aims for $225 (-4.6 %), call made on July 11, 2026, maturing on July 11, 2027 (48 d ago).

The 6 reliable analysts $225-4.6 %
The 3 other firms $244+3.5 %
How to read it: the 6 reliable firms are not filtered by optimism — 0 aim above the price, 6 below, hence their $225 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 9 ratings (last 6 months)
Strong Buy00%
Buy222%
Hold778%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about ResMed? The JPI assistant answers using our backtest data.

💰 ResMed dividend: yield, history & growth › open the full page

1.19%annual yield
📈 Steady dividend13 yrs of consecutive dividend increases
That's ~$2.40 per share per year.

📈 ResMed fundamentals: valuation, margins & growth › open the full page

P/E 22.6Net margin 26.9 %Revenue growth +8.6 %Average P/E

Revenue, net income and margin per year

Revenue Net income · hover a bar for details
2023
marg. 21 %
2024
Rev +11%Profit +14%
2025
Rev +10%Profit +37%
2026
Rev +10%Profit +9%

🔎 Detailed analyses

✅ Historical analyst reliability on RMD

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm % right i Gain vs sector i Calls i
Morgan Stanley  100% +47.2% 4
Goldman Sachs  100% +40.1% 3
Deutsche Bank  100% +25.1% 4
B of A Securities  88% +17.1% 8
Oppenheimer  80% +23.9% 5
RBC Capital  73% +4.1% 11
Needham  70% +16.7% 10
Credit Suisse 67% +8.8% 3
Keybanc  67% +3.1% 12
Baird  67% -0.4% 3
See the other 8 firms
Barclays  0% -27.2% 4
Wolfe Research  0% -12.6% 2
CLSA 33% -9.3% 3
Citigroup  40% +4.7% 5
JP Morgan  50% +3.4% 12
Macquarie  50% +15.4% 2
Mizuho  56% +14.6% 9
UBS  57% +10.8% 7

📊 What $1,000 invested in ResMed would be worth › open the full page

In short — $1,000 invested in ResMed 10 years ago would be worth $3,630 today, i.e. +14%/yr on average. Best year: 2020 (+37%), worst: 2022 (-20%). Price performance, excluding dividends.

If I'd invested $1,000 in ResMed

InvestmentWorth todayGain
1 years ago$852-15%
3 years ago$936-6%
5 years ago$917-8%
→ See ResMed's full return history + gain calculator

Return by year (ResMed)

YearReturn$1,000 invested at year start
2026 (YTD)-19%$809 (-19%)
2025+5%$852 (-15%)
2024+33%$1,133 (+13%)
→ See ResMed's full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on ResMed

Loading news…

📋 All analyst calls on RMD

Rothschild & Co
Aug 19, 26
■ Neutral neutral · not a buy · 🎯$230
Price at call : $228.44 — gap to target +1%
Today : $235.76 — gap to target -2%
🎯 on RMD : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Aug 19, 27
RBC Capital 
Aug 7, 26
■ Sector Perform neutral · not a buy · 🎯$244
Price at call : $220.05 — gap to target +11%
Today : $235.76 — gap to target +3%
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Aug 7, 27
Piper Sandler 
Aug 7, 26
■ Neutral neutral · not a buy · 🎯$225
Price at call : $220.05 — gap to target +2%
Today : $235.76 — gap to target -5%
🎯 on RMD : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Aug 7, 27
Keybanc 
Aug 7, 26
▲ Overweight · 🎯$255
Price at call : $220.05 — upside +16%
Today : $235.76 — upside +8%
🎯 on RMD : 50% (4 calls matureds) · 📊 on Health : 44.1% · -1.7% (143 calls)
in progress (365j)
matures : Aug 7, 27
Wells Fargo 
Aug 7, 26
■ Equal-Weight neutral · not a buy · 🎯$215
Price at call : $220.05 — gap to target -2%
Today : $235.76 — gap to target -9%
🎯 on RMD : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Aug 7, 27
Mizuho 
Jul 15, 26
▲ Outperform · 🎯$220
Price at call : $202.76 — upside +9%
Today : $235.76 — upside -7%
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Jul 15, 27
Citigroup 
Jul 13, 26
■ Neutral neutral · not a buy · 🎯$235
Price at call : $198.5 — gap to target +18%
Today : $235.76 — gap to target -0%
🎯 on RMD : 100% (1 call matured) · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Jul 13, 27
Jefferies 
Jul 10, 26
■ Hold neutral · not a buy · 🎯$225
Price at call : $198.5 — gap to target +13%
Today : $235.76 — gap to target -5%
🎯 on RMD : no call matured yet · 📊 on Health : 50.8% · +4.5% (380 calls)
in progress (365j)
matures : Jul 10, 27
See the other 42 calls, newest to oldest
RBC Capital 
Jul 8, 26
▲ Outperform · 🎯$276
Price at call : $208.45 — upside +32%
Today : $235.76 — upside +17%
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Jul 8, 27
Wells Fargo 
Jul 8, 26
■ Equal-Weight neutral · not a buy · 🎯$225
Price at call : $205.84 — gap to target +9%
Today : $235.76 — gap to target -5%
🎯 on RMD : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Jul 8, 27
Keybanc 
Jun 22, 26
▲ Overweight · 🎯$266
Price at call : $188.45 — upside +41%
Today : $235.76 — upside +13%
🎯 on RMD : 50% (4 calls matureds) · 📊 on Health : 44.1% · -1.7% (143 calls)
in progress (365j)
matures : Jun 22, 27
Morgan Stanley 
Jun 17, 26
■ Equal-Weight neutral · not a buy · 🎯$230
Price at call : $186.29 — gap to target +23%
Today : $235.76 — gap to target -2%
🎯 on RMD : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Jun 17, 27
Citigroup 
Jun 15, 26
▲ Buy · 🎯$270
Price at call : $193.94 — upside +39%
Today : $235.76 — upside +15%
🎯 on RMD : 100% (1 call matured) · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Jun 15, 27
RBC Capital 
May 1, 26
▲ Outperform · 🎯$321
Price at call : $209.43 — upside +53%
Today : $235.76 — upside +36%
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : May 1, 27
Wells Fargo 
May 1, 26
■ Equal-Weight neutral · not a buy · 🎯$227
Price at call : $209.43 — gap to target +8%
Today : $235.76 — gap to target -4%
🎯 on RMD : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : May 1, 27
Keybanc 
Apr 27, 26
▲ Overweight · 🎯$290
Price at call : $217.14 — upside +34%
Today : $235.76 — upside +23%
🎯 on RMD : 50% (4 calls matureds) · 📊 on Health : 44.1% · -1.7% (143 calls)
in progress (365j)
matures : Apr 27, 27
Citigroup 
Apr 9, 26
▲ Buy · 🎯$340
Price at call : $228.87 — upside +49%
Today : $235.76 — upside +44%
🎯 on RMD : 100% (1 call matured) · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Apr 9, 27
Citigroup 
Feb 2, 26
▲ Buy · 🎯$345
Price at call : $251.41 — upside +37%
Today : $235.76 — upside +46%
🎯 on RMD : 100% (1 call matured) · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Feb 2, 27
RBC Capital 
Jan 30, 26
▲ Outperform · 🎯$314
Price at call : $254.74 — upside +23%
Today : $235.76 — upside +33%
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Jan 30, 27
Piper Sandler 
Jan 30, 26
■ Neutral neutral · not a buy · 🎯$275
Price at call : $254.74 — gap to target +8%
Today : $235.76 — gap to target +17%
🎯 on RMD : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Jan 30, 27
Wells Fargo 
Jan 30, 26
■ Equal-Weight neutral · not a buy · 🎯$270
Price at call : $254.74 — gap to target +6%
Today : $235.76 — gap to target +15%
🎯 on RMD : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Jan 30, 27
Stifel 
Jan 30, 26
■ Hold neutral · not a buy · 🎯$265
Price at call : $254.74 — gap to target +4%
Today : $235.76 — gap to target +12%
🎯 on RMD : no call matured yet · 📊 on Health : 51.2% · +8.1% (299 calls)
in progress (365j)
matures : Jan 30, 27
Stifel 
Dec 18, 25
■ Hold neutral · not a buy · 🎯$260
Price at call : $242.55 — gap to target +7%
Today : $235.76 — gap to target +10%
🎯 on RMD : no call matured yet · 📊 on Health : 51.2% · +8.1% (299 calls)
in progress (365j)
matures : Dec 18, 26
Baird 
Dec 16, 25
■ Neutral neutral · not a buy · 🎯$275
Price at call : $247.34 — gap to target +11%
Today : $235.76 — gap to target +17%
🎯 on RMD : no call matured yet · 📊 on Health : 51.7% · +6.5% (298 calls)
in progress (365j)
matures : Dec 16, 26
Baird 
Nov 3, 25
▲ Outperform · 🎯$300
Price at call : $248.95 — upside +21%
Today : $235.76 — upside +27%
🎯 on RMD : no call matured yet · 📊 on Health : 51.7% · +6.5% (298 calls)
in progress (365j)
matures : Nov 3, 26
RBC Capital 
Oct 31, 25
▲ Outperform · 🎯$303
Price at call : $248.95 — upside +22%
Today : $235.76 — upside +29%
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Oct 31, 26
Keybanc 
Oct 31, 25
▲ Overweight · 🎯$299
Price at call : $246.88 — upside +21%
Today : $235.76 — upside +27%
🎯 on RMD : 50% (4 calls matureds) · 📊 on Health : 44.1% · -1.7% (143 calls)
in progress (365j)
matures : Oct 31, 26
Mizuho 
Oct 31, 25
▲ Outperform · 🎯$300
Price at call : $246.88 — upside +22%
Today : $235.76 — upside +27%
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 52.1% · +3.5% (217 calls)
in progress (365j)
matures : Oct 31, 26
Morgan Stanley 
Oct 21, 25
▲ Overweight · 🎯$304
Price at call : $268.22 — upside +13%
Today : $235.76 — upside +29%
🎯 on RMD : no call matured yet · 📊 on Health : 51.5% · +5.2% (825 calls)
in progress (365j)
matures : Oct 21, 26
Wells Fargo 
Oct 13, 25
■ Equal-Weight neutral · not a buy · 🎯$280
Price at call : $273.01 — gap to target +3%
Today : $235.76 — gap to target +19%
🎯 on RMD : no call matured yet · 📊 on Health : 48.5% · +1.2% (392 calls)
in progress (365j)
matures : Oct 13, 26
Citigroup 
Sep 18, 25
▲ Buy · 🎯$330
Price at call : $273.29 — upside +21%
Today : $235.76 — upside +40%
🎯 on RMD : 100% (1 call matured) · 📊 on Health : 53.1% · +2.5% (508 calls)
in progress (365j)
matures : Sep 18, 26
Mizuho 
Aug 1, 25
▲ Outperform · 🎯$290
Price at call : $291.44 — upside -0%
Today : $235.76 — upside +23%
Expected -0% · Actual -26% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 52.1% · +3.5% (217 calls)
-26.2%
stock -26% · XLV +22%
matured Aug 1, 26
Stifel 
Aug 1, 25
■ Hold neutral · not a buy · 🎯$270
Price at call : $291.44 — gap to target -7%
Today : $235.76 — gap to target +15%
🎯 on RMD : no call matured yet · 📊 on Health : 51.2% · +8.1% (299 calls)
in progress (365j)
matures : Aug 1, 26
RBC Capital 
Aug 1, 25
▲ Outperform · 🎯$300
Price at call : $291.44 — upside +3%
Today : $235.76 — upside +27%
Expected +3% · Actual -26% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
-26.2%
stock -26% · XLV +22%
matured Aug 1, 26
UBS 
Aug 1, 25
▲ Buy · 🎯$325
Price at call : $291.44 — upside +12%
Today : $235.76 — upside +38%
Expected +12% · Actual -26% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
-26.2%
stock -26% · XLV +22%
matured Aug 1, 26
Keybanc 
Aug 1, 25
▲ Overweight · 🎯$298
Price at call : $279.2 — upside +7%
Today : $235.76 — upside +26%
Expected +7% · Actual -23% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 50% (4 calls matureds) · 📊 on Health : 44.1% · -1.7% (143 calls)
-22.9%
stock -23% · XLV +24%
matured Aug 1, 26
Piper Sandler 
Aug 1, 25
■ Neutral neutral · not a buy · 🎯$270
Price at call : $279.2 — gap to target -3%
Today : $235.76 — gap to target +15%
🎯 on RMD : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Aug 1, 26
RBC Capital 
Jul 16, 25
▲ Outperform · 🎯$294
Price at call : $256.42 — upside +15%
Today : $235.76 — upside +25%
Expected +15% · Actual -22% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
-22.4%
stock -22% · XLV +21%
matured Jul 16, 26
Mizuho 
Jul 16, 25
▲ Outperform · 🎯$270
Price at call : $254.25 — upside +6%
Today : $235.76 — upside +15%
Expected +6% · Actual -20% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 52.1% · +3.5% (217 calls)
-20.3%
stock -20% · XLV +21%
matured Jul 16, 26
RBC Capital 
Apr 24, 25
■ Sector Perform neutral · not a buy · 🎯$255
Price at call : $235.88 — gap to target +8%
Today : $235.76 — gap to target +8%
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 42.8% · -2.4% (395 calls)
in progress (365j)
matures : Apr 24, 26
UBS 
Apr 24, 25
▲ Buy · 🎯$285
Price at call : $235.88 — upside +21%
Today : $235.76 — upside +21%
Expected +21% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 0% (2 calls matureds) · 📊 on Health : 51.5% · +3.1% (355 calls)
-5.9%
stock -6% · XLV +4%
matured Apr 24, 26
JP Morgan 
Apr 24, 25
▲ Overweight · 🎯$290
Price at call : $235.88 — upside +23%
Today : $235.76 — upside +23%
Expected +23% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 50% (2 calls matureds) · 📊 on Health : 53.8% · +5.3% (355 calls)
-5.9%
stock -6% · XLV +4%
matured Apr 24, 26
Piper Sandler 
Apr 24, 25
■ Neutral neutral · not a buy · 🎯$248
Price at call : $235.88 — gap to target +5%
Today : $235.76 — gap to target +5%
🎯 on RMD : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Apr 24, 26
Keybanc 
Apr 24, 25
▲ Overweight · 🎯$274
Price at call : $235.88 — upside +16%
Today : $235.76 — upside +16%
Expected +16% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 50% (4 calls matureds) · 📊 on Health : 44.1% · -1.7% (143 calls)
-5.9%
stock -6% · XLV +4%
matured Apr 24, 26
Keybanc 
Apr 21, 25
▲ Overweight · 🎯$269
Price at call : $214.08 — upside +26%
Today : $235.76 — upside +14%
Expected +26% · Actual +4% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 50% (4 calls matureds) · 📊 on Health : 44.1% · -1.7% (143 calls)
+3.7%
stock +4% · XLV +8%
matured Apr 21, 26
Citigroup 
Mar 5, 25
▲ Buy
Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 100% (1 call matured) · 📊 on Health : 53.1% · +2.5% (508 calls)
+12.4%
stock +12% · XLV +2%
matured Mar 5, 26
Stifel 
Mar 5, 25
■ Hold neutral · not a buy · 🎯$240
Price at call : $225.03 — gap to target +7%
Today : $235.76 — gap to target +2%
🎯 on RMD : no call matured yet · 📊 on Health : 51.2% · +8.1% (299 calls)
in progress (365j)
matures : Mar 5, 26
JP Morgan 
Jan 31, 25
▲ Overweight · 🎯$286
Price at call : $240.55 — upside +19%
Today : $235.76 — upside +21%
Expected +19% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 50% (2 calls matureds) · 📊 on Health : 53.8% · +5.3% (355 calls)
+5.9%
stock +6% · XLV +6%
matured Jan 31, 26
Keybanc 
Jan 31, 25
▲ Overweight · 🎯$280
Price at call : $240.55 — upside +16%
Today : $235.76 — upside +19%
Expected +16% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on RMD : 50% (4 calls matureds) · 📊 on Health : 44.1% · -1.7% (143 calls)
+5.9%
stock +6% · XLV +6%
matured Jan 31, 26
Piper Sandler 
Jan 31, 25
■ Neutral neutral · not a buy · 🎯$260
Price at call : $240.55 — gap to target +8%
Today : $235.76 — gap to target +10%
🎯 on RMD : no call matured yet · 📊 on Health : 46.7% · -1.3% (321 calls)
in progress (365j)
matures : Jan 31, 26

Frequently asked questions

Should I buy ResMed stock?

This isn't buy advice. For ResMed, the analyst consensus is "Hold", with an average price target of $230 (-2% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (4 calls tracked on ResMed). We show the numbers — you decide.

Is it too late to buy ResMed? How high can it go?

The most bullish analyst target on ResMed is $255 (+8% above today's price); the average is $230. That's the upside they see. Check how reliable those analysts have actually been on ResMed on our site before trusting it.

Is ResMed still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 18 analysts have a real record on ResMed, the best hitting 100% over 4 calls. Current consensus: "Hold". Make your call on data, not noise.

Should you invest in ResMed? The case for and against

The arguments for and against, one by one, from the numbers: why invest in RMD (and why hesitate).

What has ResMed's past performance been?

Historical returns and a "how much if I had invested" calculator: RMD performance & returns.

Does ResMed pay a dividend?

Yield, consistency and growth history of the dividend: RMD's dividend.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)